Diabetes remains fastest-growing MedTech market despite some risk from new drugs: analysts

Eli Lilly and Novo Nordisk shared information about a new class of diabetes and weight-loss medications at the ADA meeting. Companies have predicted that the treatments will bring in billions of dollars annually in the coming years due to links between the class of compounds, which includes Ozempic, and weight reductions of 15% and more. By altering the use of insulin, new diabetic medications could put "short-lived pressures" on MedTech firms, claim analysts at Mizuho. The question of whether demand for insulin, insulin delivery devices, and blood glucose management solutions will continue to climb in the coming years has been raised by the introduction of Following the annual  conferee new medications that regulate blood sugar and promote weight loss.